Aerovate Therapeutics (NASDAQ:AVTE - Get Free Report) posted its earnings results on Thursday. The company reported ($0.19) earnings per share for the quarter, meeting the consensus estimate of ($0.19), Zacks reports.
Aerovate Therapeutics Price Performance
AVTE traded up $0.01 on Tuesday, hitting $2.52. The company had a trading volume of 11,929 shares, compared to its average volume of 572,691. Aerovate Therapeutics has a 1-year low of $1.25 and a 1-year high of $32.42. The company's fifty day moving average price is $2.49 and its 200 day moving average price is $2.45. The stock has a market cap of $72.90 million, a price-to-earnings ratio of -0.84 and a beta of 1.01.
Aerovate Therapeutics Company Profile
(
Get Free Report)
Aerovate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial.
See Also
Before you consider Aerovate Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aerovate Therapeutics wasn't on the list.
While Aerovate Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
